Muscarinic M 3 receptors stimulate ERK1/2, the mitogen activated protein kinase pathway. The phosphorylation of the M 3 receptor by casein kinase 1 on sites in the third intracellular loop contributes to the mechanism of receptor activation of ERK1/2 by working in concert with the diacylglycerol/PKC arm of the phospholipase C signalling pathway. A mutant of the muscarinic M 3 receptor, in which most of the third intracellular (i3) loop had been deleted (M 3 -short), completely lost the ability to stimulate the ERK1/2 phosphorylation in COS-7 cells. This loss was evident despite the fact that the receptor was able to couple efficiently to the phospholipase C second messenger pathway. In co-transfected cells, M 3 -short greatly reduced the ability of M 3 to activate ERK1/2. In another set of experiments we tested the ability of a mutant M 3 /M 2 (16aa) receptor, in which the first 16 aminoacids of the i3 loop of the M 3 receptor were replaced with the corresponding segment of the muscarinic M 2 receptor to stimulate ERK1/2 phosphorylation. This mutant is not coupled to G α q but it is weakly coupled to G α i. In spite of its coupling modification, this receptor was able to stimulate ERK1/2 phosphorylation. Again, M 3 -short greatly reduced the ability of M 3 /M 2 (16aa) to activate ERK1/2 in co-transfected cells. Similar results were obtained in stable transfected CHO cells lines. In CHO-M 3 cells carbachol induced a biphasic increase of ERK1/2 phophorylation: a first increase at doses as low as 0.1 µM and a second increase starting from 10 µM. In CHO-M 3 -short and in double transfected CHO-M 3 /M 3 -short cells we observed only the lower doses increase of ERK1/2 phophorylation, no further increase was observed up to 1 mM carbachol. This suggests that in double transfected CHO cells M 3 -short is preventing the effect of the higher doses of carbachol on the M 3 receptor. In a final experiment we tested the ability of co-transfected chimeric α 2 /M 3 and M 3 /α 2 receptors to activate the ERK1/2 pathway.
Introduction
Over the past several years, it has become increasingly apparent that G-protein coupled receptors (GPCRs) interact with one another to form dimers (or heterodimers) or larger oligomeric complexes (for reviews see: 1 and 2). Despite the large number of studies that have been published on receptor dimerization it is not obvious whether the paired activation of the two halves (receptor monomers) of the dimer is required or not for a specific receptor response.
In most cases, it seems that the individual ability of a given receptor to couple with selective Gproteins is not impaired by heterodimerization and a single agonist is often sufficient to give a full receptor response (3) (4) (5) (6) (7) , even though the concomitant presence of two agonists can eventually modify this response. This suggests that the paired activation of the two receptors constituting the homo-or heterodimers is not strictly required for proper G-protein coupling. This concept can be also substantiated by the fact that the activity of non-functional GPCRs can be rescued by truncated receptors. For instance, a non-functional chimeric M 3 /M 2 muscarinic receptor, in which the corresponding region of M 2 has replaced the N-terminal i3 loop, can be re-activated by cotransfection with a truncated muscarinic M 3 receptor bearing the correct N-terminal i3 loop sequence. In this case, the dimer is formed by a full-length receptor and a per se inactive fragment, suggesting that only one half of the dimer is sufficient for the G-protein coupling (8) .
Mitogenic signals mediated by mitogen-activated protein kinases (MAPK), ERK-1 and ERK-2, can be initiated by both receptor-tyrosine kinases and by GPCRs. Recent data suggest that, besides their well characterized roles in GPCR desensitization and sequestration, β-arrestins may contribute to GPCR activation of MAPK by functioning as adaptors or scaffolding for the recruitment of these signalling molecules into a complex with agonist occupied receptors (for a review see 9). The first evidence of this is reported in the work of Luttrell et al. (1999) (10) , who demonstrated that agonist stimulation of β 2 adrenergic receptor phosphorylation leads to a rapid recruitment of β-arrestin1 that carries with it to the receptor activated c-Src. Subsequent reports showed that β-arrestins can also interact directly with component kinases of the ERK1/2 and c-Jun N-terminal kinase 3 mitogen-activated protein kinase cascades. β-arrestins have been shown to form complexes with angiotensin II type 1A receptor, cRaf-1 and ERK (11, 12) , with protease-activated receptor type 2, Raf-1 and ERK1/2 (13) , and with neurokinin-1 receptor, c-Src and ERK1/2 (14) .
In a recent study, Budd et al. (2001) (15) have shown that phosphorylation of the muscarinic M 3 receptor by casein kinase 1α on sites in the third intracellular loop contributes to the mechanism of receptor activation of ERK1/2 by working in concert with the diacylglycerol/PKC arm of the phospholipase C signalling pathway. Recruitment of β-arrestin1 to the phosphorylated third intracellular loop of the muscarinic M 3 receptor is essential in this signalling process (16) M3 muscarinic receptors, like most of the GPCRs, have been shown to form dimers (17) ; in this work we investigated to see whether the paired activation of both of the receptor components of the M3 dimer plays a role in the cascade of events leading to ERK1/2 phosphorylation.
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for the indicated times with agonists or antagonists at +37 °C. Cells were then lysed in a buffer containing 50 mM Tris (pH 7.5), 200 mM NaCl, 1 mM EDTA, 0.1% NIAPROOF, 1.5 µM pepstatine, 4 µM leupeptin, 300 nM aprotinin 0.1 mM PMSF. The samples were then incubated for 30 min at +4°C and centrifuged for 15 min at 17,000 rpm. The pellet was discharged and protein concentration was measured in the supernatant with a BIO-RAD Protein Assay Kit. Proteins were run on a 15% SDS PAGE and the extent of phosphorylation of (ERK1/2) MAP kinase was determined by immuno-blotting with antiphosphoERK (Sigma). The blots were then stripped and reblotted with the antiERK1/2 (Sigma) to control the total amount of kinases loaded. Data from separate experiments were digitized on a flatbed scanner and analysed with a Kodak scientific imaging system software.
Immuno-precipitation and Western blotting of M 3 , M 3 M 2 (16aa) and M 3 -short
For immuno-precipitation, a N-terminal hemagglutinin tagged M 3 -short (HA-M 3 -short) was used. Three days after transfection, confluent plates of cells were washed twice with sterile 0.9% NaCl and scraped with 300 µl of buffer solution A (0.2% digitonin, EDTA 1 mM in PBS) containing a cocktail of protease inhibitors (1.5 µM pepstatin, 4 µM leupeptin, 0.01 M aprotinin and 500 µM PMSF).
Lysed cells were incubated on ice for 20 minutes and then centrifuged at 6000 rpm for 10 min at +4°C. The supernatant was removed and the pellet was re-suspended in 200 µl of buffer solution B (1% digitonin, 0.5% deoxycholate, 1 mM EDTA in PBS) containing the protease inhibitor cocktail and incubated at +4°C for 1 hour. Cells were centrifuged at 17000 rpm for 20 min at +4°C and then the supernatant was recovered for immuno-precipitation.
In order to eliminate proteins that could non-specifically bind magnetic beads, the cell extract was pre-exposed to 25 µl of protein G magnetic beads for 1 hour at +4°C. A magnetic field was applied to the side of the tube and the supernatant was recovered and transferred to a clean 1.5 ml microcentrifuge tube. For immuno-precipitation, 5 µg of an anti-M 3 antibody directed against the i3-loop (Santa Cruz Biotechnology, Inc) was added to the tube and the suspension was incubated at +4°C for 1 hour. At the end of the incubation, 25 µl of protein G magnetic beads were added and incubated at +4°C for an additional hour. A magnetic field was applied to pull beads to the side of the tube and the supernatant was carefully removed.
The magnetic beads were washed with 500 µl of immuno-precipitation buffer (0.1% niaproof, 0.2 M NaCl, 1 mM EDTA, 50 mM Tris, pH 7.5) including the protease inhibitor cocktail. Bead pellets were recovered by applying a magnetic field and they were re-suspended in 30 µl of Laemli buffer (plus 150 mM dithiotreitol) and incubated at +70°C for 5 min.
A magnetic field was applied to the sample and the supernatant was recovered and loaded on 15% SDS-polyacrylamide gel. Proteins were run at 90 V for 2-3 hours and transferred to the nitrocellulose membrane for 1 hour at 100V. The co-immunoprecipitated HA-M 3 -short protein was determined by immunoblotting with an anti-HA antibody from (Sigma). Data from separate experiments were digitized on a flatbed scanner and analysed with a Kodak scientific imaging system software.
Immuno-precipitation of [ 3 H]NMS and [ 3 H]MK-912 labelled HA-M 3 /α 2 and α 2 /M 3 receptors
COS-7 cells were transfected with the chimeric HA-M 3 /α 2 and the α 2 /M 3 receptors. Three days after transfection, confluent plates of cells were washed twice with sterile 0,9% NaCl and scraped off the plate into ice-cold buffer (Buffer C) containing: 20 mM KH 2 PO 4 , 20 mM NaCl, 1 mM EDTA, 0.1 mM PMSF, 0.02% (w/v) sodium azide, 1 mM benzamide, 2 µg/ml pepstatin A, 0.2 µg/ml leupeptin, 200 µg/ml bacitracin, pH 7.6. They were homogenised in a Polytron homogeniser for 30 seconds and spun down in a centrifuge for 40 min at +4°C and 17000 rpm. This step was then Bead pellets containing the labelled HA-M 3 /α 2 and α 2 /M 3 receptors were counted with a scintillation β-counter.
Phosphatidylinositol Breakdown Assay
Transfected COS-7 cells were incubated with myo-[ 3 H]inositol (3 µCi/ml) for 48 h. Immediately prior to the experiment, the cells were washed twice with phosphate-buffered saline and incubated for 15 min in Eagle's medium containing 10 mM LiCl and 20 mM HEPES. The medium was then replaced by 0.25 ml of the same medium containing the experimental agents. After a one-hour incubation at +25°C, the reaction was arrested by the addition of 0.75 ml of 7.5% (w/v) ice-cold trichloroacetic acid, followed by a 30-min incubation on ice. The trichloroacetic acid was extracted with water-saturated diethyl ether (3 x 4 ml), and levels of IP 1 were determined by anion exchange chromatography (22) .
Adenyl cyclase assay
COS-7 cells were transfected with the plasmid(s) containing the receptor of interest plus the adenyl cyclase V. Twenty-four hours after transfection, the cells were trypsinized and recultured in 24-well plates, and after an additional 24 h, they were assayed for adenyl cyclase activity. The assay was performed in triplicate as described by Avidor-Reiss et al., (1995) (23) . In brief, the cells in the 24-well plates were incubated for 2 h with 0.25 ml/well of fresh growth medium containing 5 µCi/ml [ 3 H]adenine, and this medium was replaced with 0.5 ml/well of DMEM containing 20 mM HEPES, pH 7.4, 0.1 mg bovine serum albumin, and the phosphodiesterase inhibitors 1-methyl-3-isobutylxanthine (0.5 mM) and RO-20-1724 (0.5 mM). AC activity was stimulated by the addition of 1 µM forskolin in the presence or absence of carbachol. After 10 min of incubation at +30°C, the medium was removed and the reaction terminated by the addition of perchloric acid containing 0.1 mM unlabelled cAMP, followed by neutralization with KOH. The amount of [ 3 H]cAMP formed was determined by a two-step column separation procedure, as described by Avidor-Reiss et al., (1995) (23) .
Results
In a first set of experiments we characterized the ability of the muscarinic M 3 receptor to stimulate the phosphorylation of ERK1/2 in COS-7 cells. As shown in Fig. 2a, carbachol at (Fig. 3a) , despite the fact that this receptor was efficiently coupled to G α q as shown by the increase in phosphatidylinositol hydrolysis (Fig. 4a) .
In order to see if the M 3 -short receptor can interfere with the ability of the wild type muscarinic M 3 receptor to stimulate ERK1/2 phosphorylation, we co-transfected these two receptors together. As shown in Fig. 3a , the M 3 -short completely blocks the ability of the wild type M 3 receptor to induce ERK1/2 phosphorylation. It is interesting to note that the co-transfection of these two receptors together did not modify the extent of the IP 1 accumulation in phosphatidylinositol breakdown assays (Fig. 4a) .
In another set of experiments we tested another mutant muscarinic M 3 receptor in which 16 aminoacids of the N-terminal i3 loops were exchanged with 16 aminoacids of the M 2 [M 3 /M 2 (16aa)]. While the binding affinity of this receptor for muscarinic ligands remained unchanged, its coupling selectivity was altered. As reported by Wess et al. (1990) (20) , this receptor loses the ability to stimulate the phosphatidyl inositol hydrolysis (Fig. 4a) and acquires the ability to inhibit the accumulation of cAMP (Fig. 4b) . Regardless of its change in coupling selectivity, this receptor efficiently stimulated ERK1/2 phosphorylation (Fig. 3b) .
Pertussis toxin at a concentration of 130 ng/ml given 24 h before the assay reduced but did not abolish the ability of carbachol to stimulate ERK1/2 phosphorylation (Fig. 3b) . The magnitude of the basal phosphorylation of ERK1/2 was reduced, and after the correction for the change in the basal level, the stimulation was on average 3.29-fold in cells treated with pertussis toxin and 4.14-fold in cells untreated. This difference was statistically significant at the 0.05 level (Two tailed Paired Student's t-test ).
In order to see if the M 3 -short receptor was able to inhibit the effect of the M 3 /M 2 (16aa) to stimulate ERK1/2 phosphorylation, we co-transfected these two receptors together. Similar to what has been observed with the wild type M 3 receptor, the M 3 -short completely abolished the M 3 /M 2 (16aa) induction of ERK1/2 phosphorylation. Remarkably, the ability of the two receptors expressed together to activate the phosphatidyl inositol hydrolysis (Fig. 4a) and to inhibit the accumulation of cAMP ( Fig. 4b) was not altered, indicating that the co-expression of these two receptors does not interfere with G-protein coupling.
In a control experiment, we co-transfected the M 3 /M 2 (16aa) with the wild type M 3 receptor. In this condition carbachol was able to activate ERK1/2 phosphorylation (Fig. 3c) ; furthermore, there was no modification in the ability of the two receptors to induce the phosphatidylinositol hydrolysis (Fig. 4a) and to inhibit the accumulation of cAMP (Fig. 4b ).
An alternative explanation for the inhibition of ERK1/2 phosphorilation by M 3 -short could be that it sequesters some proteins needed for the activation of ERK1/2. To exclude this possibility, in a control experiment, we co-transfected M 3 -short with the adrenergic α 1B receptor. Stimulation of M 3 -short with carbachol (100 µM) did not interfere with the induction of ERK1/2 phosphorylation by the noradrenaline stimulated adrenergic α 1B receptor (unpublished result).
We extended our experimental observations to stable transfected CHO cell lines. CHO-M 3 and CHO-M 3 -short cells were generated previously (19) ; double transfected CHO-M 3 /M 3 -short cells, were generated by transfecting the M 3 -short receptor in CHO-M 3 cells. The relative amount of the M 3 receptor in CHO-M 3 /M 3 -short cells (detected with an antibody against the third cytoplasmic loop) was slightly decreased compared to CHO-M 3 cells ( Table 1) .
By normalizing for the B max obtained in CHO-M 3 cells, we calculated that the absolute amount of M 3 in CHO-M 3 /M 3 -short cells was 636 fmol/mg of proteins (753 * 84.5/100). Subtracting this value from the total B max we obtained that the amount of the M 3 -short receptor was 1190 fmol/mg of proteins (1826 -636).
In contrast to transiently transfected COS-7 cells, the basal level of ERK1/2 in serum starved CHO-M 3 cells was very low or undetectable. The dose response-curve of carbachol induced ERK1/2 phosphorylation in CHO-M 3 cells was biphasic, with an initial increase at lower doses of the agonist (0.1 µM) and a second increase starting at 10 µM (Fig. 5) . In contrast in CHO-M 3 -short cells the dose response-curve of carbachol induced ERK1/2 phosphorylation was monophasic. Low doses of agonist increased ERK1/2 phosphorylation and no further increase was observed up to 1 mM carbachol (Fig. 5) . Carbachol induction of ERK1/2 phosphorylation in double transfected CHO-M 3 /M 3 -short cells, was similar to CHO-M 3 -short cells; low doses of carbachol increased ERK1/2 phosphorylation and no further increase was observed with higher doses of the agonist (Fig. 5) . Carbachol up to 1 mM did not induce ERK1/2 phosphorylation in untransfected CHO cells, indicating that the effect of the agonist in stable transfected CHO cells was receptor mediated (unpublished result).
We have shown in the past that the co-transfection of chimeric adrenergic/muscarinic α 2 /M 3 and M 3 /α 2 receptors results in the rescue of the binding of muscarinic and adrenergic ligands.
Furthermore, we have shown that carbachol efficiently stimulates phosphatidylinositol hydrolysis in COS-7 cells co-transfected with these two chimeric receptors (8) . In both of these chimeric receptors, the third cytoplasmic loop is from the muscaric M 3 receptor; therefore it is likely that the activation of the adrenergic half of the reconstituted heterodimer results in the stimulation of phosphatidylinositol hydrolysis. As predicted, the adrenergic agonist clonidine was able to stimulate the phosphatidylinositol hydrolysis, even though the extent of the stimulation was markedly less than that of carbachol (Fig. 6a) . When carbachol was given in the presence of a 100 µM concentration of clonidine, the shape of the curve was not substantially different from that observed with carbachol alone, except for the fact that the curve began at 30% over the basal, due to the effect of clonidine, and the extent of stimulation at high concentrations was roughly the same (Fig.   6a ). This suggest that clonidine did not modify the affinity of carbachol for the reconstituted M 3 receptor; in accord, the shape of the [ 3 H]NMS displacement curves did not change substantially in the presence of 100 µM clonidine, suggesting that the two receptors work independently (Fig. 6b) .
COS-7 cells co-transfected with chimeric α 2 /M 3 and M 3 /α 2 receptors are a good model for testing whether the paired stimulation of a dimer is required for ERK1/2 stimulation; in fact, the only form compatible with a function in this case is a dimer, and only inactive monomers are eventually present in the cells. We started to test whether carbachol or clonidine given alone at a concentration of 100 µM were able to stimulate ERK1/2 activation. Surprisingly, neither of the agonists stimulated ERK1/2 phosphorylation, (Fig. 7) . Conversely, carbachol and clonidine given together at a concentration of 100 µM clearly activated ERK1/2 phosphorylation (Fig. 7) .
In order to make clear whether the two agonists given together stimulate ERK1/2 phosphorylation by a specific activation of the chimeric muscarinic/adrenergic heterodimer, we tested the ability of the muscarinic and the adrenergic antagonists, atropine and yohimbine, respectively, to prevent the effect of the paired carbachol/clonidine ERK1/2 stimulation. As shown in Fig. 8a and b, both antagonists effectively prevented the effect of the paired carbachol/clonidine stimulation.
We also tested whether antibodies against each of the α 2 /M 3 and M 3 /α 2 chimeric receptor were In cells co-transfected with 1 µg M 3 and 2 µg HA-M 3 -short we determine the fraction of M 3 receptor in the cell lysates before and after immunoprecipitation with anti-HA antibodies. As shown in Fig. 9c the fraction of M 3 receptor remaining in the cell lysates after immunoprecipitaion was on average 23.4%, therefore up to 76.6% was co-immunoprecipitated with HA-M 3 -short.
Conversely, the fraction of HA-M3 short receptor in the cell lysates after immunoprecipitation with the anti-M3 antibodies was 62.8% therefore up to 37.2% was co-immunoprecipitated with M 3 . If we consider that the amount of HA-M 3 -short receptor transfected was twice as much that of the M 3 , these data make sense.
Discussion
It is now well established that G-protein coupled receptors form homo-and heterodimers. While the mechanism(s) of dimerization still remains to be elucidated, it is becoming increasingly apparent that this phenomenon is important for several receptor functions. One of the critical points in receptor homo-and heterodimerization is determining whether the paired activation of the dimer is required or not for specific receptor functions.
Most of the reports dealing with receptor dimerization indicate that the individual stimulation of one of the two interacting receptors in co-transfected cells is often sufficient for G-protein activation (3-7). On the other hand, the simultaneous activation of both receptors with selective agonists can change the pharmacology of one or both of the two receptors (6) . These data indicate that heterodimerization by itself does not necessarily interfere with G-protein coupling. This conclusion is supported also by the fact that heterodimerization between receptors that bind distinct G-proteins often leaves the coupling selectivity of each receptor unaltered. For instance, β 2 adrenergic receptors that couple to stimulatory G-proteins, or δ and κ opioid receptors that couple to inhibitory G-proteins, form heteromeric complexes, but heterodimerization does not significantly alter the ligand binding or the coupling properties of these receptors (24) .
Consistently with these data, we observed that the co-transfection of a mutant muscarinic M 3 receptor, which couples preferentially to G α i, the M 3 /M 2 (16aa), with an other mutant M 3 receptor M 3 -short that couples to G α q, leaves the coupling selectivity of these two receptors unaltered, despite the fact that they form dimers. It is interesting to note that the binding properties of these two receptors were identical (19) but that the potency of carbachol in the phosphatidyl inositol breakdown assay and in the cAMP assay were quite different, indicating that in spite of their interaction these two receptors are rather independent in their G-protein coupling properties.
Certainly, we must consider that only a fraction of the entire population of receptors in the membrane forms M 3 -short/M 3 /M 2 (16aa) heterodimers; it is possible, therefore, that the residual monomers (or homodimers) are responsible for the observed responses. This consideration obviously applies to the above mentioned adrenergic/opioid heterodimer as well.
More direct evidence that heterodimerization can leave the coupling property of each receptor unaltered comes from our experiment with chimeric adrenergic/muscarinic receptors (8, 19) . In the past we have shown that chimeric α 2 /M 3 and M 3 /α 2 receptors, when co-transfected together, reconstitute the binding activity of the wild type adrenergic and muscarinic receptors, while neither of the two chimeras was able to bind adrenergic or muscarinic ligands. These results imply that in cells co-transfected with the two chimeras the only active receptor is the heterodimer α 2 /M 3 -M 3 /α 2 . In the present work we proved this belief by immunoprecipitating the α 2 /M 3 and HA-M 3 /α 2 receptors labelled with cholinergic and adrenergic ligands. Only when the α 2 /M 3 and HA-M 3 /α 2 receptors were transfected together, selective antibodies immunoprecipitated receptor bound cholinergic and adrenergic ligands, confirming that the only active receptor is the heterodimer
Since in both chimeras the third cytoplasmic loop was from the muscarinic M 3 receptor, it was not surprising that the stimulation of both the muscarinic and the adrenergic counterparts of this heterodimer led to the increase in the phosphatidyl inositol hydrolysis. Yet we observed that the binding affinity of carbachol in the presence of clonidine was not significantly modified. These data support the view that the single activation of part of a heterodimer is sufficient for G-protein activation, and that the occupancy of both sites of the heterodimer can perhaps only modify the coupling efficiency.
Besides G-protein coupling, a G-protein coupled receptor can activate mitogenic signals mediated by mitogen-activated protein kinases (MAPK), ERK-1 and ERK-2 (25) . We analysed the activation of this pathway to see if it requires the paired activation of a receptor dimer. For this purpose we used the muscarinic M 3 receptor that has been shown to form dimers (17) and to stimulate MAPK. In a recent study, Budd et al. (2001) (15) have shown that phosphorylation of the muscarinic M 3 receptor by casein kinase 1α on sites in the third intracellular loop contributes to the mechanism of receptor activation of ERK1/2 by working in concert with the diacylglycerol/PKC arm of the phospholipase C signalling pathway. They came to this conclusion by using a modified M 3 receptor in which a large part of the i3 loop was removed.
In our study, using an analogous mutant of the muscarinic M 3 receptor, M 3 -short, we confirmed the importance of the i3 loop in the stimulation of ERK1/2 phosphorylation. Since the recruitment of β-arrestin1 to the phosphorylated third intracellular loop of the muscarinic M 3 receptor is essential in this signalling process (16) , and in the light of the fact that β-arrestins may contribute to GPCR activation of MAPK, by functioning as adaptors or scaffolding for the recruitment of these signalling molecules into a complex with agonist occupied receptors (for a review see 9) , it is very likely that this segment of the receptor concurs to the activation of ERK1/2 by binding β-arrestin 1, which in turn functions as an adaptor or scaffolding for the recruitment and the activation of c-Src. When we co-transfected the M 3 -short receptor with the wild type M 3 receptor, the carbachol stimulation of ERK1/2 phosphorylation in COS-7 cells was greatly subdued. This inhibition was not due to a shift in the dose-response curve to carbachol since doses as high as 1 mM were ineffective. Indirectly, by measuring the fraction of the M 3 receptor in the cell lysates after coimmunoprecipitation, we calculated that the amount of M 3 receptor co-immunoprecipitated with M 3 -short was as much as 76.6% of the total M 3 receptor expressed in the membrane. This suggests that most of the M 3 receptor forms heterodimers.
It remained to be established whether the effect of the M 3 -short was due to its lack of the i3 loop or to an induced alteration of the functional activity of the M 3 . Since both of these receptors are coupled to G α q, and there is no difference in binding and coupling efficiency, we addressed this question by using the mutant M 3 /M 2 (16aa) mentioned above. Similarly to what has been observed with the wild type M 3 receptor, the M 3 -short also prevented the ability of M 3 /M 2 (16aa) to stimulate ERK1/2 phosphorylation. Despite this effect on ERK1/2, as mentioned above, the M 3 -short did not modify the coupling efficacy of M 3 /M 2 (16aa), indicating that the effect on ERK1/2 was not due to a functional alteration of the receptor. To further support the lack of the i3 loop A likely explanation for these results is that, for an efficient activation of the ERK1/2 pathway to take place, both of the receptors in the dimer have to bear a full-length i3 loop. Since, as mentioned before, recruitment of β-arrestin1 to the phosphorylated third intracellular loop of the muscarinic (10), the activation of the β 2 AR leads to a rapid recruitment of β-arrestin 1 that carries with it to the receptor activated c-Src. Conversely, the β 1 AR interact weakly with β-arrestins (26) , therefore it is likely that its interaction with the β 2 AR in the heterodimer prevents β-arrestin binding and consequently ERK1/2 activation. This led us to speculate that for an efficient coupling of the heterodimer to β-arrestins both of the receptors must bind this protein efficiently.
This idea is also based on a recent study on the organization of rhodopsin in native membranes (27) .
Arrestin, the cognate β-arrestins in the visual system, has a bipartite structure of two structurally homologous seven-stranded β-sandwiches forming two putative rhodopsin-binding groves that are separated by 3.8 nm (28, 29) . The positive charge arrangement of the surface of the rhodopsin dimer matches the negative charges on arrestin, thus, one arrestin monomer is likely to bind one rhodopsin dimer.
The evidence reported above indicate that dimers rather than monomers are required for the cascade of events that lead to ERK1/2 phosphorylation, but this does not answer the question of whether or not the two receptors constituting the dimer have to be activated at the same time. In order to address this issue, we performed experiments with chimeric muscarinic/adrenergic α 2 /M 3 and M 3 /α 2 receptors. As mentioned above, these two receptors exist only as heterodimers, and they were constructed in a way that both chimeras carried the i3 loop of the muscarinic M 3 receptor. We tested to see whether the single muscarinic or adrenergic agonist (carbachol or clonidine) was able to stimulate ERK1/2 phosphorylation. Surprisingly, and in contrast to what has been observed with G-protein coupling, both agonists given alone were unable to induce ERK1/2 phosphorylation.
Conversely, when the two agonists were given together there was a clear activation of ERK1/2. This effect was specific, as demonstrated by the fact that both the adrenergic and muscarinic antagonists prevented ERK1/2 phosphorylation induced by the paired stimulation of carbachol and clonidine.
These results demonstrated that, in order to have an activation of ERK1/2 by this heterodimer, both the adrenergic and muscarinic receptor components must be activated.
In conclusion the data in this paper raise the possibility that in certain conditions the stimulation of ERK1/2 phosphorylation requires the paired activation of a receptor dimer. For inositol phosphate breakdown assay, cells were pre-labelled for 48 h with 3 µCi/ml 
